Pillstats
Rx only · Tablet, Chewable · Oral

Methylphenidate Hydrochloride

Methylphenidate Hydrochloride

5 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US16 NDCs
5 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)6901
US makers5 labelers
Packages16
DEA / ScheduleCII

US acquisition costNADAC · per unit

Average across 6 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.606$1.21$1.82$2.43Dec 2025Apr 2026Jul 2026
$2.059
Latest avg · Jul 22, 2026
+2%
Since Dec 17, 2025
5
Active US suppliers
44%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

6.4K13K19K26K2025 Q12025 Q22025 Q32025 Q42026 Q1
22K
Rx · 2026 Q1
1.1M
Units dispensed
-2%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it5 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Bryant Ranch Prepackrepackager4SUPPLYING
XLCare Pharmaceuticals Inc.unknown3SUPPLYING
Rising Pharma Holdings, Inc.unknown3SUPPLYING
Camber Pharmaceuticals, Inc.unknown3SUPPLYING
Lupin Pharmaceuticals,Inc.unknown3SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Feb 7, 2022
    RECALLRecall (Class II): Methylphenidate Hydrochloride Chewable Tablets, 2.5 mg, 100-count bottle, Rx Only, Manufactured for: Rising Pharmaceuti…

    Failed Tablet Specifications: Recall of this drug product was voluntarily initiated by the manufacturer due to a market complaint, which stated that a tablet in the sealed bottle was twice larger in size when compared to the remaining tablets. This complaint is second of its kind. — Recalling firm: RISING PHARMACEUTICALS — Nationwide in the USA